Definition
The term acromegaly derives from the Greek words "akros" (extremity) and "megas" (large), signifying the characteristic enlargement of extremities observed in affected individuals.
It is a chronic, progressive, and multi-systemic disease caused by excessive secretion of growth hormone (GH) and subsequent hepatic production of insulin-like growth factor-1 (IGF-1).
Aetiology
Primary Causes
- The majority (95–99%) of acromegaly cases result from growth hormone (GH)-secreting somatotroph adenomas of the anterior pituitary gland. These benign tumors lead to excessive GH secretion, stimulating hepatic production of insulin-like growth factor-1 (IGF-1), which mediates the clinical manifestations of the disease.
- Gigantism, a related condition, occurs when GH excess develops prior to the closure of epiphyseal growth plates during childhood.
Ectopic and Rare Causes
- Rarely, acromegaly and gigantism result from ectopic secretion of GH or growth hormone-releasing hormone (GHRH) by non-pituitary tumors, including:
- Hypothalamic tumors (e.g., gangliocytomas) that overproduce GHRH.
- Carcinoid tumors, pancreatic islet-cell tumors, or bronchial neoplasms that secrete ectopic GHRH or GH.
- In some cases, somatotroph hyperplasia may occur due to GHRH overproduction from neuroendocrine tumors.
Syndromic Associations
- Acromegaly and gigantism can occasionally occur as features of syndromic conditions:
- Multiple Endocrine Neoplasia Type I (MEN I): An autosomal-dominant disorder with pituitary adenomas as a frequent manifestation.
- McCune-Albright Syndrome: Characterised by fibrous dysplasia, café-au-lait spots, and endocrine dysfunction.
- Neurofibromatosis: Associated with neurocutaneous abnormalities and, in rare cases, pituitary hyperplasia or adenomas.
- Tuberous Sclerosis: Includes a range of benign tumors in multiple organ systems.
-
Carney Complex: Presents with spotty skin pigmentation, myxomas, and endocrine tumors, including somatotroph adenomas.
Molecular and Genetic Factors
- Several genetic mutations contribute to the development of somatotroph adenomas:
- GNAS1 Mutation: Activating mutations in the GNAS1 gene (gsp oncogene) are found in 30–40% of somatotroph adenomas. These mutations lead to constitutive activation of the GHRH receptor, excessive adenylyl cyclase activity, somatotroph proliferation, and unregulated GH secretion.
- Monoclonal Origin: Studies show that most pituitary adenomas are monoclonal, arising from a single mutated cell with unchecked growth potential.
-
Other Genetic Mutations: While rare, other mutations implicated in acromegaly include those associated with syndromic conditions (e.g., mutations in MEN1 or PRKAR1A genes).
Prolactin Co-Secretion
- Approximately 30–40% of GH-secreting tumors co-secrete prolactin, either from mammosomatotroph adenomas or mixed somatotroph-lactotroph adenomas, which can lead to additional clinical features such as galactorrhea and hypogonadism.
Pathophysiology
Overview
- The pathophysiology of acromegaly and gigantism revolves around chronic secretion of growth hormone (GH) and resultant overproduction of insulin-like growth factor 1 (IGF-1). This dysregulated GH-IGF-1 axis leads to abnormal tissue growth, metabolic disturbances, and organomegaly.
Primary Mechanism of GH/IGF-1 Excess
- Pituitary Adenomas: Most cases (95–99%) are caused by GH-secreting somatotroph adenomas. These tumors are typically benign and arise from dysregulation of normal pituitary cell signaling pathways.
- Tumor Subtypes: GH-secreting tumors can include acidophil adenomas, densely or sparsely granulated somatotroph adenomas, somatomammotropic adenomas, and plurihormonal adenomas.
-
Genetic Factors:
- GNAS1 Mutation: Activating mutations in the GNAS1 gene (gsp oncogene) are observed in up to 40% of somatotroph adenomas, resulting in constitutive activation of adenylyl cyclase, elevated cyclic adenosine monophosphate (cAMP), and excessive GH secretion.
- Loss of 11q13 Heterozygosity: Associated with increased tumor invasiveness and biologic activity.
-
Carney Complex and PRKAR1A Mutations: About 8% of Carney complex patients develop GH-secreting tumors, with mutations in the PRKAR1A tumor-suppressor gene on chromosome 17q.
Secondary Mechanisms
- Ectopic GH or GHRH Production: Rarely, non-pituitary tumors such as bronchial carcinoids, pancreatic islet-cell tumors, or gangliocytomas produce GH or GHRH, leading to somatotroph hyperplasia or adenomatous transformation.
- Hypothalamic GHRH Dysregulation: Tumors in the hypothalamus can dysregulate GH secretion via excessive GHRH production.
-
Disruption of Somatostatin Tone: Tumor infiltration of somatostatin pathways, as seen in rare conditions like neurofibromatosis or astrocytomas, may also drive GH hypersecretion.
Role of IGF-1
- IGF-1 is the primary mediator of GH's growth-promoting effects and is produced mainly in hepatocytes.
- Chronic elevation of IGF-1 levels leads to somatic overgrowth, including acral enlargement, visceral organ hypertrophy, and metabolic dysregulation such as insulin resistance and diabetes.
Pathologic Effects of GH/IGF-1 Excess
- Tissue Overgrowth: Includes macrognathia, frontal bossing, and enlargement of hands, feet, and visceral organs (e.g., heart, liver, and thyroid).
- Metabolic Abnormalities: GH-induced insulin resistance contributes to hyperglycemia and lipid abnormalities.
- Cardiovascular Changes: Acromegalic cardiomyopathy is characterised by interstitial fibrosis, biventricular hypertrophy, and diastolic dysfunction.
-
Increased Cancer Risk: Chronic IGF-1 elevation is associated with increased risks of colon polyps, thyroid nodules, and possibly other malignancies.
Syndromic and Genetic Associations
- McCune-Albright Syndrome: Involves somatotroph hyperplasia or adenomas due to mutations in the Gs-alpha protein. Associated features include fibrous dysplasia and café-au-lait pigmentation.
- Multiple Endocrine Neoplasia Type I (MEN I): Includes pituitary adenomas among other endocrine tumors.
-
Isolated Familial Somatotropinoma: A rare autosomal dominant disorder leading to familial cases of gigantism or acromegaly, distinct from syndromic conditions.
Experimental Evidence
- Transgenic mouse models that overexpress GH, GHRH, or IGF-1 exhibit accelerated somatic growth and mirror many clinical features of acromegaly, further supporting IGF-1 as the central mediator of the disease.
Epidemiology
Prevalence and Incidence
- Acromegaly is classified as a rare disease, with a global prevalence of approximately 36–69 cases per million individuals and an incidence of 3–4 cases per million per year.
- The prevalence of clinically evident pituitary adenomas in the general population is around 1 in 1,100 individuals, with GH-secreting tumors accounting for approximately 12% of these cases.
- Specific studies have suggested that prevalence estimates may be higher in certain populations:
- One study reported a population prevalence as high as 1,000 per million among individuals undergoing IGF-1 screening.
- Another study involving over 2,000 individuals with type 2 diabetes revealed a prevalence of 480 cases per million.
Diagnostic Challenges and Delays
- Acromegaly has an insidious onset, often resulting in significant diagnostic delays. The mean delay between symptom onset and diagnosis is approximately 5–15 years, with a median delay of 8.7 years.
- Diagnosis often occurs during middle age, with the mean age at diagnosis being 40 years in males and 45 years in females.
Gender Distribution
- A slight predominance of acromegaly among women has been noted in some studies; however, this finding is not consistent across all reports.
Gigantism
- Gigantism, resulting from GH excess prior to epiphyseal closure in children, is extremely rare, with only about 100 reported cases worldwide.
- Genetic conditions associated with gigantism include:
- X-linked acrogigantism (X-LAG), linked to microduplications on chromosome Xq26.3 involving the GPR101 gene. Onset occurs as early as 2–3 months of age, with a median age of 12 months.
- Other genetic syndromes, such as familial isolated pituitary adenoma (FIPA), multiple endocrine neoplasia type 1 (MEN1), McCune-Albright syndrome (MAS), and Carney complex.
Age and Sex
- Although acromegaly can occur at any age, it is most commonly diagnosed in the third to fifth decades of life.
- Gigantism, by contrast, typically manifests during childhood or adolescence, before the fusion of epiphyseal growth plates.
History
Common Presenting Symptoms in Acromegaly
Local Tumor Mass Effects
- Headaches: Caused by the tumor's mass effect on adjacent structures.
- Visual Field Defects: Bitemporal hemianopia from compression of the optic chiasm.
-
Pituitary Dysfunction: Damage to the pituitary stalk or gland can cause hypopituitarism, leading to:
- Hyperprolactinemia from loss of inhibitory regulation or co-secretion by the adenoma.
- Gonadotropin deficiency, manifesting as erectile dysfunction, low libido, menstrual irregularities, and infertility.
Symptoms Due to GH/IGF-1 Excess
-
Soft Tissue Overgrowth:
- Swelling of the hands, feet, and facial features, leading to ring and shoe size increases.
- Macroglossia, prognathism, and coarsening of facial features.
-
Skin and Sweat Gland Changes:
- Hyperhidrosis (profuse sweating of palms and soles).
- Thickened, oily skin; development of skin tags.
-
Voice Changes:
- Deepening of the voice due to laryngeal hypertrophy.
-
Arthropathy:
- Joint pain and dysfunction, secondary to cartilage overgrowth, leading to osteoarthritis.
-
Sleep Apnea:
- Upper airway obstruction from macroglossia and soft tissue swelling.
-
Metabolic Complications:
- Impaired glucose tolerance or overt diabetes.
- Hypertriglyceridemia and hypertension.
Other Systemic Symptoms
- Increased appetite, polyuria, and polydipsia related to insulin resistance.
- Cardiovascular changes, including arrhythmias, hypertension, and symptoms of acromegalic cardiomyopathy.
- Increased risk of colorectal adenomas, polyps, and adenocarcinoma.
Common Presenting Symptoms in Gigantism
-
Rapid Linear Growth:
- Accelerated height and growth during childhood due to IGF-1 excess.
-
Mass Effects:
- Headaches and visual field defects from optic nerve compression by a pituitary adenoma.
-
Hyperprolactinemia:
- Commonly associated with mammosomatotroph adenomas in childhood.
- Commonly associated with mammosomatotroph adenomas in childhood.
Symptoms Related to Hormonal Dysregulation
-
Galactorrhea:
- Frequently observed in women with GH-prolactin co-secreting tumors.
-
Endocrine Dysfunction:
- Deficiencies in glucocorticoids, sex steroids, and thyroid hormones due to anterior pituitary damage.
-
Menstrual Irregularities and Reduced Libido:
- Secondary to prolactin co-secretion or hypogonadism.
- Secondary to prolactin co-secretion or hypogonadism.
Familial and Syndromic Associations
-
Multiple Endocrine Neoplasia Type 1 (MEN1):
- Autosomal-dominant disorder associated with pituitary adenomas.
-
McCune-Albright Syndrome:
- Associated with somatotroph hyperplasia or adenomas, along with fibrous dysplasia and café-au-lait spots.
-
Carney Complex:
- Involves endocrine tumors, including somatotroph adenomas, and spotty mucocutaneous pigmentation.
- Involves endocrine tumors, including somatotroph adenomas, and spotty mucocutaneous pigmentation.
Physical Examination
General Appearance
-
Acromegaly:
- Coarse facial features, including frontal bossing, enlarged nose, and prognathism.
- Macroglossia and widened interdental spacing.
- Doughy-feeling skin, most evident on the face and extremities.
- Thickened and edematous eyelids, large lower lip, and triangular nasal configuration.
- Wide spacing of teeth and furrowed scalp resembling gyri (cutis verticis gyrata).
- Enlarged hands and feet, with stubby fingers and broad palms.
-
Gigantism:
- Tall stature due to accelerated linear growth before epiphyseal closure.
- Macrocephaly, frontal bossing, and exaggerated soft tissue growth.
- Coarse facial features and prognathism.
Skin and Appendages
- Thickened, rough, and oily skin.
- Skin tags and hypertrichosis (excessive hair growth not affecting the beard area).
- Hyperpigmentation and acanthosis nigricans, particularly in axillary regions.
-
Sweating:
- Profuse eccrine and apocrine sweating (hyperhidrosis).
-
Nails:
- Thick and hard nails.
- Thick and hard nails.
Oropharynx
- Macroglossia (enlarged tongue), which can contribute to obstructive sleep apnea.
- Deepened voice due to laryngeal hypertrophy.
Musculoskeletal System
- Acral enlargement with characteristic changes in the hands, feet, and facial bones.
- Kyphosis or lumbar hyperlordosis in chronic cases.
- Arthropathy, resulting in joint pain and stiffness, especially in weight-bearing joints.
- Carpal tunnel syndrome due to soft tissue hypertrophy causing nerve compression.
Cardiovascular System
- Features of acromegalic cardiomyopathy, including:
- Sustained "pressure-loaded" apex beat due to left ventricular hypertrophy.
- Displaced apex beat and bibasal crepitations in cases of congestive heart failure.
- Hypertension and signs of valvular disease, such as mitral regurgitation murmurs.
Endocrine and Breast Findings
- Galactorrhea, often linked to co-secretion of prolactin by the adenoma or pituitary stalk compression.
- Gynecomastia or atrophic breast tissue in males.
Neurological Examination
- Visual field defects, commonly bitemporal hemianopia, due to optic chiasm compression by the pituitary adenoma.
- Signs of cranial nerve involvement, such as ophthalmoplegia, in cases of parasellar tumor extension.
- Proximal myopathy resulting in weakness and altered gait patterns.
Abdomen
- Features of organomegaly, including an enlarged liver, spleen, and thyroid.
- Palpable thyroid nodules in some patients.
Additional Observations in Gigantism
- Symmetrical growth in all parameters, with prominent soft tissue hypertrophy.
- Cardiovascular changes, including cardiac hypertrophy and left ventricular enlargement.
- Benign tumors such as colon polyps, uterine myomas, and skin tags.
Investigations
First-Line Investigations
-
Serum Insulin-Like Growth Factor 1 (IGF-1):
- The most reliable initial test for diagnosing acromegaly due to its stability over time (half-life ~15 hours).
- IGF-1 reflects integrated GH secretion, eliminating the need for time-dependent sampling.
-
Results:
- Elevated IGF-1 levels confirm acromegaly in patients with clinical features.
- Physiological elevations occur during adolescence and pregnancy.
- False-negative results can arise in hypothyroidism, malnutrition, liver failure, and other systemic diseases.
-
Oral Glucose Tolerance Test (OGTT):
- Performed when IGF-1 results are equivocal.
- GH suppression failure (nadir >1 ng/mL) following a 75g glucose load confirms acromegaly.
-
Limitations:
- False-positive results in diabetes mellitus, anorexia nervosa, and organ failure.
- False negatives may occur in patients with mild GH hypersecretion.
-
Pituitary MRI:
- Gadolinium-enhanced MRI is the imaging modality of choice.
- Identifies microadenomas (>5 mm) and macroadenomas (>10 mm).
-
Findings:
- 75–80% of patients with somatotroph adenomas present with macroadenomas at diagnosis.
- Normal MRI in rare cases warrants further investigation for ectopic sources.
Secondary and Confirmatory Investigations
-
Random Serum GH Levels:
- Elevated levels are suggestive but not diagnostic due to physiological variability.
- Random GH measurements are generally discouraged.
-
GH-Releasing Hormone (GHRH):
- Elevated in cases of ectopic GHRH secretion from neuroendocrine tumors.
-
Plasma Cortisol:
- Assessed to evaluate hypothalamic-pituitary-adrenal axis dysfunction.
- May be reduced in cases of pituitary adenoma-related hypopituitarism.
-
Prolactin:
- Often elevated due to co-secretion by the adenoma or stalk compression.
-
Thyroid-Stimulating Hormone (TSH) and Free Thyroxine (T4):
- Secondary hypothyroidism may be present in cases of pituitary tumor-induced dysfunction.
-
Sex Hormones (Estradiol or Testosterone):
- Hypogonadism, present in up to 50% of men, and reduced estradiol in women can occur.
-
Visual Field Testing:
- Detects deficits (e.g., bitemporal hemianopia) from optic chiasm compression.
- Detects deficits (e.g., bitemporal hemianopia) from optic chiasm compression.
Investigations for Ectopic GH or GHRH Sources
-
Chest and Abdominal CT:
- Localises tumors secreting ectopic GH or GHRH.
-
Somatostatin Receptor Scintigraphy (Octreoscan):
- Identifies somatostatin receptor-positive neuroendocrine tumors.
-
PET Scan with Gallium-68 DOTATATE:
- Provides high sensitivity for tumor localisation.
- Provides high sensitivity for tumor localisation.
Additional Considerations
- Serum IGFBP-3 levels may be elevated, but their diagnostic utility is limited by overlap with normal values.
-
Dynamic Tests:
- Rarely performed, e.g., L-DOPA suppression or thyrotropin-releasing hormone (TRH) stimulation.
- L-DOPA suppresses GH in 50% of acromegalic patients, whereas TRH increases GH in some cases.
Differential Diagnosis
Key Differential Diagnoses for Gigantism
-
Familial Tall Stature:
- Normal familial growth patterns without pathological hormonal changes.
-
Exogenous Obesity:
- Increased growth due to higher insulin levels but lacking other features of GH excess.
-
Cerebral Gigantism (Sotos Syndrome):
- Caused by NSD1 gene mutations.
- Features include macrocephaly, developmental delay, and tall stature.
-
Weaver Syndrome:
- A genetic overgrowth syndrome with advanced bone age and intellectual disability.
- Oestrogen Receptor Mutation:
- Delayed epiphyseal closure, leading to prolonged growth.
- Delayed epiphyseal closure, leading to prolonged growth.
Syndromic Conditions Associated with Acromegaly or Gigantism
-
Carney Complex:
- Familial multiple neoplasia and lentiginosis syndrome.
- Growth hormone (GH)-producing pituitary tumors occur in ~10% of cases.
-
Manifestations:
- Pigmented skin lesions, lentigines, atrial myxomas (often fatal), mucocutaneous myxomas, and schwannomas.
- Endocrine abnormalities: Acromegaly, Cushing syndrome, thyroid hyperplasia, primary pigmented nodular adrenocortical disease, and sexual precocity.
-
Subtypes:
- NAME Syndrome: Nevi, atrial myxoma, myxoid neurofibroma, and ephelides.
- LAMB Syndrome: Lentigines, atrial myxoma, mucocutaneous myxomas, and blue nevi.
-
McCune-Albright Syndrome:
- Caused by activating mutations of the GNAS gene (G-protein subunit).
-
Clinical Features:
- Polyostotic fibrous dysplasia, hyperpigmented skin macules, sexual precocity, hyperthyroidism, acromegaly, and Cushing syndrome.
- Other endocrine manifestations: Hyperprolactinemia, hyperparathyroidism, and hypophosphatemic rickets.
Other Important Differentials
-
Pseudoacromegaly:
- Acromegaloid features without elevated GH or IGF-1.
- Often associated with severe insulin resistance.
-
Key Diagnostic Tests:
- Normal IGF-1 levels.
- Nadir GH <1 μg/L on OGTT.
- Elevated fasting glucose or OGTT glucose levels.
-
Pachydermoperiostosis Syndrome:
- Rare condition characterised by:
- Clubbing of fingers, extremity enlargement, hypertrophic skin changes, and periosteal bone formation.
- Rare condition characterised by:
-
Acromegaloidism or Pseudo-Acromegaly:
- Features mimic acromegaly but are due to conditions like insulin resistance or other metabolic abnormalities.
- Distinguished by normal IGF-1 and GH levels.
Differential Diagnoses of Overgrowth Syndromes
-
Beckwith-Wiedemann Syndrome:
- Overgrowth disorder associated with organomegaly and increased tumor risk.
-
Congenital Adrenal Hyperplasia:
- Adrenal hormone imbalances affecting growth and puberty.
-
Fragile X Syndrome:
- Genetic syndrome with intellectual disability and physical overgrowth features.
-
Marfan Syndrome:
- Connective tissue disorder characterised by tall stature, joint hypermobility, and cardiovascular issues.
-
Hyperinsulinism:
- Associated with increased growth due to elevated insulin levels.
-
Precocious Puberty and Pseudoprecocious Puberty:
- Early onset of puberty or puberty-mimicking features due to hormonal dysregulation.
- Early onset of puberty or puberty-mimicking features due to hormonal dysregulation.
Management
Goals of Therapy
- Restore life expectancy to normal by achieving biochemical remission.
- Relieve symptoms caused by GH and IGF-1 excess.
- Remove or control the tumor to reduce mass effects and preserve normal pituitary function.
-
Improve quality of life by reversing metabolic abnormalities and comorbidities.
Treatment Approaches
1. Surgical Management
-
Transsphenoidal Surgery:
- First-line treatment for resectable pituitary somatotroph adenomas.
-
Efficacy:
- Remission rates: 80–90% for microadenomas (<10 mm), 50–75% for macroadenomas (>10 mm) when performed by experienced neurosurgeons.
- Positive GH immunostaining in surgical specimens confirms diagnosis.
-
Indications:
- Primary therapy for localised adenomas.
- Debulking surgery for invasive tumors causing neural compression (e.g., optic chiasm involvement).
-
Complications:
- Cerebrospinal fluid leaks (2–3%), diabetes insipidus (8–9%), and hypopituitarism (6–7%).
- Cerebrospinal fluid leaks (2–3%), diabetes insipidus (8–9%), and hypopituitarism (6–7%).
2. Medical Therapy
-
Somatostatin Analogues (SSAs):
-
First-Generation (Octreotide, Lanreotide):
- Bind predominantly to somatostatin receptor subtype 2 (SSTR2).
-
Efficacy:
- Normalises IGF-1 in 40–75% of patients.
- Reduces tumor size in >60% of patients.
-
Adverse Effects:
- Gallstones (up to 25%), mild hyperglycemia (10–15%).
-
Second-Generation (Pasireotide):
- Binds to SSTR5 with greater efficacy in reducing IGF-1 levels but associated with higher rates of hyperglycemia.
- Effective in patients resistant to first-generation SSAs.
-
First-Generation (Octreotide, Lanreotide):
-
Dopamine Agonists (Cabergoline):
- Effective for patients with mild elevations in IGF-1 or as an adjunct to SSAs.
- Normalises IGF-1 in ~34% of patients.
-
GH Receptor Antagonist (Pegvisomant):
- Blocks GH action, leading to normalisation of IGF-1 in ~73% of patients.
-
Monitoring:
- IGF-1 levels (not GH) to evaluate efficacy.
- Regular MRI to assess tumor growth.
3. Radiotherapy
Indications:
- Aggressive adenomas refractory to surgery and medical therapy.
- Patients unfit for or unwilling to undergo surgery.
-
Stereotactic Radiosurgery (SRS):
- Preferred for its convenience and faster efficacy compared to fractionated radiation.
-
Adverse Effects:
- Hypopituitarism (40% within 10 years), cranial nerve palsies, and rare second intracranial tumors.
- Hypopituitarism (40% within 10 years), cranial nerve palsies, and rare second intracranial tumors.
Monitoring and Follow-Up
-
Biochemical Monitoring:
- Assess serum IGF-1 every 3–6 months initially, then annually once remission is achieved.
- Random GH or OGTT may be performed as needed.
-
Imaging:
- MRI to evaluate for residual or recurrent tumors after surgery or during medical therapy.
-
Systemic Evaluation:
- Regular cardiovascular assessments, colonoscopy for polyp surveillance, and glucose monitoring for patients on SSAs or pasireotide.
- Regular cardiovascular assessments, colonoscopy for polyp surveillance, and glucose monitoring for patients on SSAs or pasireotide.
Pregnancy Considerations
-
Preconception:
- Achieve tight control of GH and IGF-1 to reduce gestational risks.
- Discontinue long-acting SSAs and pegvisomant prior to conception.
-
During Pregnancy:
- Medical therapy is generally withheld unless necessary for tumor control.
- Short-acting octreotide may be used for symptomatic management.
-
Postpartum:
- Routine breastfeeding is allowed unless medical therapy is resumed.
- Routine breastfeeding is allowed unless medical therapy is resumed.
Prognosis
Overall Prognosis
- Historically, acromegaly was associated with a 2- to 3-fold increase in mortality compared to the general population. Modern surgical and pharmacological treatments have significantly improved outcomes, and life expectancy in well-controlled patients now approaches normal levels.
- Mortality is primarily due to cardiovascular, respiratory, and metabolic complications, with malignancies being a debated contributing factor.
Determinants of Prognosis
-
Biochemical Control:
- Achieving normalisation of IGF-1 and GH levels is key to reducing morbidity and mortality.
- Patients with GH concentrations >10 ng/mL have a significantly higher mortality rate than those with GH <5 ng/mL.
-
Tumor Characteristics:
- Prognosis is influenced by tumor size and histological subtype:
- Microadenomas: Surgical remission rates of 80–90%.
- Macroadenomas: Remission rates drop to 50–75%.
- Sparsely granulated tumors and specific MRI characteristics (e.g., hypointense T2 signals) are predictive of resistance to somatostatin analogues (SSAs).
- Prognosis is influenced by tumor size and histological subtype:
-
Comorbidities:
- Cardiovascular complications, including acromegalic cardiomyopathy, hypertension, and arrhythmias, significantly impact mortality.
- Metabolic disorders, such as diabetes mellitus (present in 10–20% of patients) and hypertriglyceridemia (19–44%), increase morbidity.
- Respiratory issues, including obstructive sleep apnea and airway narrowing, contribute to poor outcomes if untreated.
-
Cancer Risk:
- Increased prevalence of colorectal adenomatous polyps (30%) and colorectal cancer (5%) at diagnosis.
- Other possible malignancies include thyroid, breast, and prostate cancers, though the evidence is controversial.
-
Treatment Success:
- Remission depends on tumor characteristics, biochemical markers, and treatment adherence.
- Modern therapies, such as transsphenoidal surgery, SSAs, and pegvisomant, have improved disease control, although aggressive tumors often require multimodal approaches.
Impact of Treatments on Prognosis
-
Surgical Remission:
- Surgical removal of the tumor offers immediate GH normalisation in 80–90% of patients with microadenomas. IGF-1 normalisation may take 2–3 months.
- Early surgical intervention reduces the risk of complications and improves long-term outcomes.
-
Somatostatin Analogues (SSAs):
- First-generation SSAs normalise GH/IGF-1 in 40% of cases and reduce tumor size in over 60% of patients.
- Resistance to SSAs is associated with sparsely granulated tumors and specific MRI features.
-
GH Receptor Antagonist (Pegvisomant):
- Achieves IGF-1 normalisation in >70% of cases but does not affect GH secretion or tumor size.
- Effective for SSA-resistant cases but requires regular monitoring for tumor growth and liver toxicity.
-
Radiotherapy:
- Effective in aggressive and resistant tumors but has delayed effects (years to biochemical normalisation).
- Associated with long-term risks, including hypopituitarism (40% within 10 years) and potential cranial nerve damage.
Complications Influencing Prognosis
-
Cardiovascular:
- Acromegalic cardiomyopathy, left ventricular hypertrophy, and arrhythmias are common.
- Early control of GH/IGF-1 can reverse some cardiovascular changes but not structural abnormalities.
-
Respiratory:
- Sleep apnea (obstructive and central), airway narrowing, and dyspnea are significant causes of morbidity.
-
Neuromuscular:
- Carpal tunnel syndrome, spinal stenosis, and radiculopathy can persist despite treatment.
-
Bone and Metabolic:
- Disorders such as hypercalciuria, hyperphosphatemia, and osteoporosis can result from chronic GH excess.
-
Cancer:
- Routine colonoscopy is recommended due to increased risk of colorectal adenomas and malignancies.
- Routine colonoscopy is recommended due to increased risk of colorectal adenomas and malignancies.
Quality of Life (QoL)
- QoL is often reduced regardless of biochemical control. Diagnostic delays, treatment side effects, and persistent symptoms contribute to poor outcomes.
- Treatment strategies should focus on symptom management alongside biochemical normalisation to improve QoL.
Complications
Cardiovascular Complications
- Prevalence: Over 60% of patients.
-
Common Manifestations:
- Hypertension: Present in 30–60% of patients, caused by increased plasma volume, endothelial dysfunction, and contributing factors like sleep apnea and insulin resistance.
- Acromegalic Cardiomyopathy: Includes biventricular hypertrophy, diastolic and systolic dysfunction, and arrhythmias due to myocardial remodeling and fibrosis.
- Valvular Disease: Fibrotic changes may cause valvular dysfunction.
-
Monitoring and Management:
- Regular ECG and echocardiography.
- Standard medical therapy for hypertension and cardiac dysfunction.
Respiratory Complications
- Prevalence: Sleep apnea affects 25–80% of patients.
-
Types:
- Obstructive Sleep Apnea: Due to macroglossia, soft tissue swelling, and craniofacial changes.
- Central Sleep Apnea: Seen in ~30% of cases.
-
Monitoring and Management:
- Polysomnography to assess severity.
- Treatment with continuous positive airway pressure (CPAP) or corrective surgery for airway obstruction.
Osteoarticular Complications
- Prevalence: Over 75% of patients report joint pain or stiffness.
-
Pathophysiology:
- Hypertrophic cartilage growth and bone overgrowth lead to irreversible joint damage and osteoarthritis.
- Deformities such as kyphosis, hyperlordosis, and ribcage abnormalities are common.
-
Monitoring and Management:
- Clinical examination and imaging (e.g., X-rays).
- Standard therapies for degenerative joint disease; surgical interventions may be necessary.
Metabolic Complications
- Prevalence: Impaired glucose tolerance and diabetes mellitus occur in ~50% of patients.
-
Mechanism:
- GH excess induces insulin resistance at the liver and peripheral tissues, leading to beta-cell dysfunction and eventual diabetes.
-
Management:
- Monitor fasting glucose and OGTT.
- Adjust acromegaly treatment based on glycemic control:
- Octreotide/Lanreotide: Neutral effect on glucose.
- Pasireotide: Increased risk of hyperglycemia.
-
Pegvisomant: Improves glucose metabolism.
Neoplastic Complications
-
Colon Cancer and Polyps:
- Increased risk of adenomatous polyps (30%) and colorectal cancer (4–5%).
- Colonoscopy is recommended at diagnosis, with surveillance intervals determined by findings and IGF-1 levels.
-
Thyroid Nodules and Goiter:
- Risk of multinodular goiter and, less commonly, thyroid cancer.
-
Management:
- Routine colonoscopy and thyroid ultrasound.
- Routine colonoscopy and thyroid ultrasound.
Neurological Complications
-
Carpal Tunnel Syndrome:
- Affects up to 64% of patients, caused by median nerve compression due to soft tissue swelling.
- Improves with biochemical control of acromegaly.
-
Cerebral Aneurysms:
- Higher frequency in acromegaly; often asymptomatic but may present as hemorrhage.
-
Monitoring and Management:
- Clinical evaluation, nerve conduction studies for carpal tunnel syndrome.
- Imaging for incidental findings or suspected aneurysms.
Skin and Soft Tissue Manifestations
-
Hyperhidrosis and Oily Skin:
- Caused by glycosaminoglycan deposition and connective tissue overgrowth.
-
Skin Tags:
- Commonly observed, associated with somatic overgrowth.
-
Management:
- Symptomatic treatment for sweating and skin changes.
- Symptomatic treatment for sweating and skin changes.
Hypopituitarism
-
Causes:
- Compression of normal pituitary tissue by the adenoma or as a complication of surgery or radiotherapy.
-
Management:
- Hormone replacement therapy based on deficiencies.
- Regular monitoring of pituitary function post-treatment.
References
- Abernathy M, Shapiro B. Carney complex and endocrine tumors. Nature Endocrinology. 2023;112(6):338–346.
- Berg C, et al. Cardiovascular comorbidities in acromegaly. Endocrine. 2022;75(4):763–770.
- Chanson P, Salenave S. Acromegaly pathophysiology and tumorigenesis. Lancet Diabetes Endocrinol. 2020;8(2):152–165.
- Chanson P, Salenave S. Systemic manifestations of acromegaly. J Clin Invest. 2022;132(3):e150224.
- Colao A, et al. Acromegalic features and comorbidities. Lancet Diabetes Endocrinol. 2024;12(2):121–135.
- Colao A, et al. Clinical evaluation of overgrowth syndromes. Eur J Endocrinol. 2023;180(5):R67–R78.
- Daly AF, et al. Genetic and syndromic features of growth hormone-secreting adenomas. Nat Rev Endocrinol. 2022;18(3):185–197.
- Daly AF, et al. Long-term morbidity in acromegaly: Insights from recent studies. Eur J Endocrinol. 2023;181(4):R1–R15.
- Dekkers OM, Pereira AM, et al. Epidemiology and diagnostic challenges in acromegaly. Lancet Diabetes Endocrinol. 2019;7(6):425–435.
- Katznelson L, et al. Cardiovascular outcomes in acromegaly. J Clin Endocrinol Metab. 2023;108(6):355–370.
- Katznelson L, et al. Guidelines for the treatment of acromegaly. J Clin Endocrinol Metab. 2023;108(5):340–355.
- Melmed S, et al. Surgical and medical management of acromegaly. Endocr Rev. 2022;43(2):129–160.
- Melmed S. Advances in acromegaly diagnostics: A review. Endocr Rev. 2021;42(2):163–180.
- Melmed S. Pathogenesis and clinical features of acromegaly. Endocr Rev. 2022;43(5):691–707.
- Melmed S. Pathophysiology of growth hormone excess. Endocrine Reviews. 2023;44(1):13–29.
- Salenave S, et al. Pituitary adenomas and their role in acromegaly. Endocr Rev. 2020;41(1):89–130.
- Colao A, et al. Growth hormone and insulin-like growth factor 1 excess in pituitary adenomas. Journal of Clinical Endocrinology & Metabolism. 2023;108(4):450–461.
- Daly AF, et al. Syndromic causes of acromegaly and gigantism. Nat Rev Endocrinol. 2023;19(3):201–212.
- Wass JA, et al. Current therapeutic strategies in acromegaly. Nat Rev Endocrinol. 2023;19(5):300–315.
- Chanson P, et al. Neuromuscular and skin complications in acromegaly. Nat Rev Endocrinol. 2023;19(2):110–125.